Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $23M with net income of −$15M.
Q1 2026 key financials · XBRL
- Revenue
- $23M
- Net income
- −$15M
- Operating margin
- -20.1%
- Gross margin
- 19.2%
- EPS (diluted)
- −$0.43
Source: XBRL data from the LIFECORE BIOMEDICAL, INC. DE (LFCR) Q1 2026 10-Q on SEC EDGAR. USD.
LIFECORE BIOMEDICAL, INC. DE Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $23.2M, down 34% YoY; CDMO $15.8M, down 24%, and HA manufacturing $7.4M, down 48%
- Gross margin 19.2% vs 28.0% YoY; gross profit $4.5M vs $9.8M
- Worst segment HA manufacturing; gross profit down $5.7M from lower volume and manufacturing absorption
- Cash $20.8M; $17.3M revolving availability; no revolver borrowings at March 31, 2026
- Outlook: further efficiency gains expected from ERP, procurement strategies, and business transformation leadership; headwinds include customer demand and financing needs
Risk Factors
- No risk-factors section provided in the submitted excerpt
- No new or changed risks identifiable from the available text
- No regulatory, legal, operational, competitive, market, or financial risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIFECORE BIOMEDICAL, INC. DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.